Varicella zoster virus infection in pediatric oncology patients

Yıl 2006, Cilt: 21 Sayı: 3, 115 - 118, 01.04.2006

Sema Doğan Vural Gülnur Tokuç Gül Özçelik Seda Ceylani Güleç Ela Erdem Tülay Olgun

Öz

OBJECTIVES Varicella-zoster virus (VZV) infection may lead to serious complications and death in immunocompromised patients. Although there were researches which aim to decrease complications by vaccination and antiviral prophylaxis; there is stil no definitive protocols. In this study, we wanted to determine the frequency and clinical progress of VZV infections in patients with malignant diseases in whom prophylaxis was not used routinely during chemotherapy. METHODS Datas of 30 patients (12 females, 18 males; median age 6 years; range 1 to 13 years) in pediatric oncology department who were exposed to VZV during their chemotheraphy between January 2001 and December 2004 were retrospectively examined. RESULTS In 23 of patients there was fever. Skin lesions were widespread, but they were non-hemorhogic or infected and were crusted approximotely in 6.5 days. In one patient liver enzymes were eleveted. In others systemic complications were not seen. Patients taking approximately 8 days of intravenous acyclovir were discharged from hospital without any complication. In our patients VZV infections were benignly progressed. Early treatment with acyclovir might decrease the complications. But in spite of treatment there might be seriously progressed cases. CONCLUSION In our country where vaccination for VZV is not performed routinely to healthy children; observation of large series with multidisciplinary studies of oncology and infectious diseases clinics may aid us to determine if prophylaxis is needed or not.

Anahtar Kelimeler

Acyclovir, Herpesvirus 3, Human, Retrospective Studies, Neoplasms, Child, Immune System

Çocuk onkoloji hastalarımızda varisella-zoster virüs enfeksiyonları

Öz

AMAÇ Varisella-zoster virüs enfeksiyonu kanserli hastalarda ciddi komplikasyonlara ve ölüme neden olabilir. Aşılama ve antiviral proflaksiyle komplikasyonları azaltmayı amaçlayan çalışmalar olmakla birlikte kesin protokoller yoktur. Çalışmamızda proflaksinin rutin kullanılmadığı kanserli hastalarda bu enfeksiyonun sıklığının ve klinik seyrinin belirlenmesi amaçlandı. GEREÇ VE YÖNTEM Çocuk onkolojisi kliniğinde Ocak 2001-Aralık 2004 arasında tedavi görürken varisella-zoster virüs enfeksiyonu saptanan 30 hastanın (12 kız, 18 erkek; ort. yaş 6 yıl; dağılım 1-13 yıl) kayıtları retrospektif olarak incelendi. BULGULAR Hastaların 23'ünde ateş saptandı. Cilt lezyonları yaygın, ancak hemorajik veya enfekte değildi; ortalama 6.5 günde kabuklandı. Karaciğer enzimleri yükselen bir hasta dışında sistemik yayılım olmadı. Ortalama sekiz gün intravenöz asiklovir alan hastalar komplikasyonsuz taburcu edildi. Gecikilmeden asiklovir tedavisi başlanılan hastalarda varisella-zoster virüs enfeksiyonları selim seyirli oldu. Ancak tedaviye rağmen ağır seyreden vakalar olabilmektedir. SONUÇ Sağlıklı çocuklarda rutin aşılamanın yapılmadığı ülkemizde onkoloji ve enfeksiyon kliniklerinin ortak çalışmaları ile daha geniş serilerin izlemi, proflaksinin gerekli olup olmadığını belirlemede yol gösterici olacaktır.

Anahtar Kelimeler

Asiklovir, çocuk, neoplazm/immünoloji/tedavi, varisella-zoster.

Kaynakça

• 1. Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975;56(3):388-97.
• 2. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 1987;80(4):465-72.
• 3. Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989;320(14):892-7.
• 4. Izawa T, Ihara T, Hattori A, Iwasa T, Kamiya H, Sakurai M, et al. Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics 1977;60(6):805-9.
• 5. Buda K, Tubergen DG, Levin MJ. The frequency and consequences of varicella exposure and varicella infection in children receiving maintenance therapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1996;18(2):106-12.
• 6. Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 1986;78(4 Pt 2):757-62.
• 7. Heath RB, Malpas JS, Kangro HO, Ward A, McEniery JM, Kingston JE. Efficacy of varicella vaccine in patients with solid tumours. Arch Dis Child 1987;62(6):569-72.
• 8. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993;92(2):219-22.
• 9. Ogilvie MM. Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 1998;36 Suppl 1:31-8.
• 10. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002;13(1):12-21.
• 11. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2(7892):1288-90.
• 12. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78(4 Pt 2):748-56.
• 13.[No authors listed] Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996;45(RR-11):1-36.
• 14. Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 1988;85(2A):99-101.
• 15. Paker SA, Gülez P, Vergin C, Özbek A. The efficacy of monodose varicella vaccine in pediatric cancer patients. Ege T›p Dergisi 2002;41(4):225-8.